S4 Ep11: Treating Untreatable Diseases with Genetic Medicine

Our understanding of genetics is critical to understanding the cause of diseases, allowing scientists to target the root cause of diseases to better treat – and even cure – patients. For patients with so-called “untreatable diseases,” such as Alzheimer’s and Parkinson’s, the possibility of a finding a cure through genetic medicine offers great hope. This week, guest host Andrew Adams, vice president of genetic medicines and neurodegeneration research at Lilly – overseeing the research and development of novel therapeutic modalities, including oligonucleotide therapeutics, RNA therapeutics and other emerging platforms – is joined by Ruth Gimeno, vice president of diabetes research and clinical investigation, and Michelle Lynn Hall, associate vice president of genetic medicine at Lilly. The group discusses what is dubbed as the “medicine of the future,” focusing on the advancements in genetic medicine, obstacles faced when developing genetic therapeutics and the hope and promise genetic medicine brings to patients who have so-called “untreatable” diseases.